The molecular axis hnRNPU/circKCNK2/EDC4/IL-11 aggravates osteolytic bone metastasis of RCC

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bone metastasis is a significant complication of renal cell carcinoma (RCC), leading to poor outcomes and limited treatment options.
• Understanding the molecular mechanisms driving RCC bone metastasis is crucial for developing effective therapies.

Purpose of the Study:

• To identify key molecular players involved in RCC bone metastasis.
• To elucidate the role of circKCNK2 in osteoclast differentiation and bone destruction.
• To explore potential therapeutic strategies targeting circKCNK2.

Main Methods:

• High-throughput screening of circRNA expression in primary RCC and bone metastasis samples.
• Investigating the effect of circKCNK2 overexpression on osteoclast differentiation and IL-11 secretion.
• Analyzing the molecular interaction of circKCNK2 with EDC4 and its impact on P-body function.
• Examining the influence of the tumor microenvironment (acidic pH) on circKCNK2 expression via hnRNPU.

Main Results:

• circKCNK2 (hsa_circ_0016459) was identified as significantly upregulated in RCC bone metastases.
• Overexpression of circKCNK2 promotes osteoclast differentiation and bone destruction by increasing IL-11 secretion.
• circKCNK2 disrupts P-body function by interacting with EDC4, leading to increased IL-11 mRNA and STAT-3 activation.
• Acidic microenvironment decreases hnRNPU, leading to increased circKCNK2 production in bone metastases.
• An anti-IL-11 strategy may be more beneficial than denosumab for high circKCNK2 expressing RCC.

Conclusions:

• circKCNK2 plays a critical role in linking P-bodies to the IL-11/STAT-3 signaling pathway in RCC bone metastasis.
• circKCNK2 is a potential therapeutic target for managing RCC bone metastasis.
• Targeted gene delivery systems for circKCNK2 hold promise for future RCC treatment strategies.